{"id":787363,"date":"2022-05-18T20:00:13","date_gmt":"2022-05-18T18:00:13","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/"},"modified":"2023-07-11T12:16:22","modified_gmt":"2023-07-11T10:16:22","slug":"verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/","title":{"rendered":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer"},"content":{"rendered":"Award to Conduct Phase 1b\/2 Clinical Trial of VS-6766 and Defactinib Combination in Addition to Standard of Care Chemotherapy with Objective of Increasing Response Rate and Survival\n\n\nTrial to Evaluate a Promising Approach for More Complete Blockade of Tumorigenic Signaling\n\nBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first \u201cTherapeutic Accelerator Award\u201d from the Pancreatic Cancer Network (PanCAN). The Award will support a Phase 1b\/2 clinical trial of the Company\u2019s lead investigational candidates, RAF\/MEK Clamp, VS-6766, with FAK inhibitor, defactinib, to evaluate whether a more complete b<div class=\"leaky_paywall_message_wrap\"><div id=\"leaky_paywall_message\"><a href=\"https:\/\/bebeez.it\/abbonati\/\">Abbonati<\/a> o <a href=\"https:\/\/bebeez.it\/mio-account\/\">Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Award to Conduct Phase 1b\/2 Clinical Trial of VS-6766 and Defactinib Combination in Addition to Standard of Care Chemotherapy with Objective of Increasing Response Rate and Survival Trial to Evaluate a Promising Approach for More Complete Blockade of Tumorigenic Signaling BOSTON&#8211;(BUSINESS WIRE)&#8211;Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-787363","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Award to Conduct Phase 1b\/2 Clinical Trial of VS-6766 and Defactinib Combination in Addition to Standard of Care Chemotherapy with Objective of Increasing Response Rate and Survival Trial to Evaluate a Promising Approach for More Complete Blockade of Tumorigenic Signaling BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-18T18:00:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T10:16:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer\",\"datePublished\":\"2022-05-18T18:00:13+00:00\",\"dateModified\":\"2023-07-11T10:16:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\"},\"wordCount\":1482,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\",\"name\":\"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-05-18T18:00:13+00:00\",\"dateModified\":\"2023-07-11T10:16:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/","og_locale":"en_US","og_type":"article","og_title":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez","og_description":"Award to Conduct Phase 1b\/2 Clinical Trial of VS-6766 and Defactinib Combination in Addition to Standard of Care Chemotherapy with Objective of Increasing Response Rate and Survival Trial to Evaluate a Promising Approach for More Complete Blockade of Tumorigenic Signaling BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients [&hellip;]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/","og_site_name":"BeBeez","article_published_time":"2022-05-18T18:00:13+00:00","article_modified_time":"2023-07-11T10:16:22+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer","datePublished":"2022-05-18T18:00:13+00:00","dateModified":"2023-07-11T10:16:22+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/"},"wordCount":1482,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/","name":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-05-18T18:00:13+00:00","dateModified":"2023-07-11T10:16:22+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-awarded-pancreatic-cancer-action-networks-first-therapeutic-accelerator-award-to-evaluate-the-combination-of-vs-6766-and-defactinib-in-front-line-metastatic-pancreatic-cance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Verastem Oncology Awarded Pancreatic Cancer Action Network\u2019s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/787363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=787363"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/787363\/revisions"}],"predecessor-version":[{"id":890858,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/787363\/revisions\/890858"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=787363"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=787363"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=787363"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=787363"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=787363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}